Semaglutide in Nonalcoholic Fatty Liver Disease
Non-alcoholic Fatty Liver Disease
About this trial
This is an interventional treatment trial for Non-alcoholic Fatty Liver Disease focused on measuring Semaglutide, Non-alcoholic Fatty Liver Disease, Obesity, Type 2 Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria: Patients diagnosed with NAFLD by non-invasive methods in the form of abdominal US or MRI, confirmed by a Fibroscan scan with CAP to assess the quantity of hepatic steatosis and severity of fibrosis up to 21 weeks before the start of the study and after treatment. Primary obesity with body mass index (BMI) > 30. Type 2 diabetes mellitus. Exclusion Criteria: Type 1 diabetes mellitus. DM, which is treated with insulin glargine. Alcohol consumption. Patients had bariatric surgery. Hepatitis C virus, hepatitis B virus, HIV. Patients with peptic ulcer disease. Secondary obesity originated from hypothalamic or endocrinal disorders. Other causes of CLD. Decompensated liver disease. History of pancreatitis (acute or chronic). Hepato-biliary disorders. ALT and AST values > 5 times of upper normal limits. Severe cardiac disease. Patients treated with GLP-1 agonist within 90 days before screening. Patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
Sites / Locations
- Zagazig UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
Active Comparator
NAFLD1
NAFLD2
NAFLD3
Hepatic steatosis
Hepatic steatosis
Hepatic steatosis